The Ohio State University Wexner Medical Center is a multidisciplinary academic medical center located in Columbus, Ohio, United States, on the main campus of The Ohio State University.

There are 2,260 beds in Ohio State University Wexner Medical Center.

During the past decade, Ohio State University Wexner Medical Center conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 2 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 2 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ohio State University Wexner Medical Center" #1 sponsor was "Celgene" with 3 trials, followed by "ImmunoGen, Inc." with 2 trials sponsored, "Seagen Inc." with 2 trials sponsored, "Leap Therapeutics, Inc." with 1 trials sponsored and "Yale University" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ohio State University Wexner Medical Center" #1 collaborator was "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 3 trials as a collaborator, "Gynecologic Oncology Group" with 3 trials as a collaborator, "Belgian Gynaecological Oncology Group" with 2 trials as a collaborator, "Genmab" with 2 trials as a collaborator and "Genentech, Inc." with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Ohio State University Wexner Medical Center" are "Crohn Disease" (3 trials), "Cervical Cancer" (2 trials), "Endometrial Cancer" (2 trials), "Epithelial Ovarian Cancer" (2 trials) and "Fallopian Tube Cancer" (2 trials). Many other conditions were trialed in "Ohio State University Wexner Medical Center" in a lesser frequency.

Most popular intervention types in "Ohio State University Wexner Medical Center" are "Drug" (9 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Ozanimod" (3 trials), "Bevacizumab" (2 trials), "Carboplatin" (2 trials), "Paclitaxel" (2 trials) and "Pembrolizumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Ohio State University Wexner Medical Center" are 6 trials for "Female" genders and 3 trials for "All" genders.

Currently, there are NaN active trials in "Ohio State University Wexner Medical Center". undefined are not yet recruiting, 3 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Ohio State University Wexner Medical Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Ohio State University Wexner Medical Center, 2 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".